Table 1 Baseline clinical characteristics of patients in the training cohort, internal and external validation cohorts.

From: Multicenter development of a deep learning radiomics and dosiomics nomogram to predict radiation pneumonia risk in non-small cell lung cancer

Clinical characteristics

Training cohort (n = 113)

Internal cohort (n = 49)

External cohort (n = 83)

Without RP2

With RP2

p

Without RP2

With RP2

p

Without RP2

With RP2

p

Age media (year)

59.99 ± 8.40

63.10 ± 6.04

0.07

61.12 ± 8.86

61.18 ± 8.60

0.98

64.61 ± 9.80

65.92 ± 7.49

0.56

Gender

 Male (%)

60 (81.08)

30 (76.92)

0.78

27 (84.38)

12 (70.59)

0.44

44 (74.58)

19 (79.17)

0.87

 Female (%)

14 (18.92)

9 (23.08)

5 (15.62)

5 (29.41)

15 (25.42)

5 (20.83)

Smoking

 Yes (%)

54 (72.97)

25 (64.10)

0.45

26 (81.25)

12 (70.59)

0.62

37 (62.71)

17 (70.83)

0.65

 No (%)

20 (27.03)

14 (35.90)

6 (18.75)

5 (29.41)

22 (37.29)

7 (29.17)

Emphysema

 Yes (%)

21 (28.38)

10 (25.64)

0.93

9 (28.12)

5 (29.41)

1.00

20 (33.90)

12 (50.00)

0.26

 No (%)

53 (71.62)

29 (74.36)

23 (71.88)

12 (70.59)

39 (66.10)

12 (50.00)

Pathology

 Adenocarcinoma

32 (43.24)

12 (30.77)

0.28

8 (25.00)

9 (52.94)

0.10

29 (49.15)

8 (33.33)

0.28

 SCC

42 (56.76)

27 (69.23)

24 (75.00)

8 (47.06)

30 (50.85)

16 (66.67)

 

T stage

 I

7 (9.46)

4 (10.26)

0.31

1 (3.12)

4 (23.53)

0.02

11 (18.64)

2 (8.34)

0.62

 II

22 (29.73)

8 (20.51)

6 (18.75)

7 (41.18)

18 (30.51)

8 (33.33)

 III

18 (24.32)

6 (15.38)

7 (21.88)

1 (5.88)

10 (16.95)

6 (25.00)

 IV

27 (36.49)

21 (53.85)

18 (56.25)

5 (29.41)

20 (33.90)

8 (33.33)

Lymphocytes

1.77 ± 0.56

1.65 ± 0.48

0.31

1.60 ± 0.60

1.54 ± 0.66

0.75

1.36 ± 0.54

1.80 ± 0.55

0.001

Neutrophils

3.88 ± 2.28

3.23 ± 1.25

0.23

3.67 ± 1.38

3.29 ± 1.62

0.21

3.63 ± 1.92

4.31 ± 2.74

0.56

Monocytes

0.46 ± 0.22

0.47 ± 0.17

0.89

0.52 ± 0.20

0.47 ± 0.18

0.44

0.52 ± 0.24

0.64 ± 0.37

0.29

Platelets

229.96 ± 62.78

229.67 ± 82.86

0.51

227.84 ± 81.26

215.00 ± 43.09

0.78

239.80 ± 107.43

236.29 ± 79.95

0.90

NLR

2.35 ± 1.60

2.12 ± 1.00

0.91

2.54 ± 1.37

2.62 ± 1.77

0.52

3.03 ± 2.06

2.58 ± 1.58

0.33

PLR

144.78 ± 78.52

150.44 ± 63.37

0.50

157.56 ± 65.53

177.73 ± 112.9

0.92

202.01 ± 132.63

143.08 ± 61.06

0.04

LMR

5.62 ± 5.97

3.87 ± 1.59

0.26

3.52 ± 1.94

3.74 ± 1.99

0.81

3.63 ± 3.76

4.30 ± 4.74

0.22

V5Gy

50.17 ± 12.07

51.17 ± 8.94

0.96

52.90 ± 9.67

55.01 ± 7.32

0.44

40.82 ± 14.16

39.81 ± 11.17

0.75

V10Gy

34.90 ± 10.03

37.39 ± 6.89

0.47

36.69 ± 8.41

39.52 ± 5.42

0.22

29.26 ± 9.74

30.40 ± 8.88

0.62

V20Gy

22.39 ± 6.61

25.30 ± 4.84

0.05

24.12 ± 4.84

27.41 ± 3.45

0.02

20.12 ± 6.50

21.85 ± 6.16

0.28

V30Gy

14.64 ± 4.93

17.74 ± 3.89

0.001

15.93 ± 3.07

19.98 ± 3.44

0.001

14.69 ± 5.10

16.43 ± 4.56

0.16

MLD

1233.88 ± 301.29

1366.37 ± 234.91

0.04

1291.64 ± 218.20

1482.74 ± 180.57

0.003

1126.24 ± 345.77

1194.07 ± 296.77

0.40

  1. Comparisons between patients with and without grade ≥ 2 radiation pneumonitis (RP2) were performed using appropriate statistical tests. Values were presented as mean ± standard deviation or n (%), and p-values indicate the significance of differences between groups.
Back to article page